Status:

TERMINATED

Efficacy of a Novel App-based Migraine Treatment Platform - a Pilot Study

Lead Sponsor:

Norwegian University of Science and Technology

Collaborating Sponsors:

Ullevaal University Hospital

Conditions:

Migraine Disorders

Eligibility:

All Genders

12-18 years

Phase:

NA

Brief Summary

This study evaluates biofeedback delivered through a smartphone as a treatment for migraine in adolescents. Three out of four participants will receive treatment as smartphone delivered biofeedback tr...

Detailed Description

Biofeedback is a behavioral treatment without known side effects. In biofeedback patients learn control over bodily reactions through feedback visualised on a screen. Typical bodily reactions that are...

Eligibility Criteria

Inclusion

  • diagnosis of migraine with or without aura according to ICHD-3
  • two to eight migraine attacks per month
  • written informed consent signed by guardians, or by adolescent if age between 16-18 years.

Exclusion

  • participant not speaking Norwegian
  • reduced sensibility, hearing or vision to a degree that impairs proper use of the app
  • serious psychiatric or neurologic disease and
  • currently using migraine prophylaxis.

Key Trial Info

Start Date :

January 11 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 29 2020

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT04106505

Start Date

January 11 2019

End Date

April 29 2020

Last Update

July 8 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Oslo Universitetssykehuse, Ullevål

Oslo, Norway, 0450

2

St. Olavs Hospital

Trondheim, Norway, 7030